¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Immune Oncology Forum 2019_From the basics for CRA/CRC & Young investigators : 2019-07-12±³À°ÀÏÀÚ : 2019-07-12
±³À°Àå¼Ò : ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F)
±³À°ÁÖÁ¦ :
KSMO Immune Oncology Forum 2019_From the basics for CRA/CRC & Young investigatorsÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : Á¶¼ºº¹
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo@ksmo.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í ȸ¿ø : ¹«·á (»çÀüµî·Ï, ÇöÀåµî·Ï) ºñȸ¿ø - »çÀüµî·Ï CRC 10,000 / CRA 20,000 / ±âŸ 30,000 ºñȸ¿ø - ÇöÀåµî·Ï CRC 20,000 / CRA 30,000 ±âŸ 40,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 14:00~14:25 Immune Checkpoint Regulation in Cancer À±½Å±³(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 14:25~14:50 Immune Checkpoint Inhibitors in Cancer: Biomarker/Cancer type-based Approvals °ÀºÁÖ(°í´ë±¸·Îº´¿ø)
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 14:50~15:15 Combination stragtegies of Immune Checkpoint Inhibitors in Cancer: Failure and Success ¹Ú±Ç¿À(¾ç»êºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 15:15~15:40 Predictive biomarkers beyond PD-L1 expression and Tumor Mutational Burden ¿ÁÂù¿µ(¼¿ï´ëÇб³º´¿ø)
ÈÞ½Ä 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 15:40~16:00 Coffee Break ()
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 16:00~16:25 iRECIST and Endpoints in Immune Checkpoint Inhibitors À̼öÁ¤(°æºÏ´ëÇб³º´¿ø)
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 16:25~16:50 Immune-related Adverse Events and Managements Á¶»óÈñ(ȼøÀü³²´ëÇб³º´¿ø)
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 16:50~17:15 Translational Research in Immune Checkpoint Inhibitors Á¤Çö¾Ö(ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø)
±³À°½Ã°£ 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 17:15~17:40 New Emerging Immune Checkpoint Inhibitors in Cancer È«¹ÎÈñ(¿¬¼¼¾Ïº´¿ø)
Åä·Ð 07-12 ¼¿ï´ëÇб³ ¾î¸°À̺´¿ø ÀÓ»óÁ¦1°ÀÇ½Ç (1F) 17:40~18:00 Q&A ()